Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug LY4302814 tested in healthy volunteers for first time

NCT ID NCT07566338

Recruiting now Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing the safety and tolerability of a new drug called LY4302814 in 150 healthy volunteers. Participants will receive either the drug or a placebo, and researchers will monitor side effects and how the body processes the drug. The study lasts about 6 months and includes an overnight stay. No therapeutic benefit is expected for participants; the goal is to gather essential safety data for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LY4302814

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fortrea Clinical Research Unit

    RECRUITING

    Daytona Beach, Florida, 32117, United States

    Contact Phone: •••-•••-••••

    Contact

  • Lilly Centre for Clinical Pharmacology

    RECRUITING

    Singapore, 138623, Singapore

    Contact Phone: •••-•••-••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.